If you are a member of the general public and not a healthcare professional, NOVELTY study investigator or AstraZeneca Medical employee, please CLICK HERE to see information tailored to you.

21st December, 2020

NOVELTY at ERS 2020

Home > News & events > NOVELTY at ERS 2020

We are pleased to announce that six NOVELTY abstracts were presented as ePosters at the virtual European Respiratory Society (ERS) Congress 2020 on 7–9 September – you can read summaries of these ePosters here. The related abstracts have now been published in a supplement to the online version of the European Respiratory Journal. The presentations cover the following topics:

Comparison of spirometric markers of severity and reversibility in patients with asthma and/or COPD
Clinical factors associated with baseline blood eosinophils among patients with asthma or COPD
Factors associated with physician assessment of severity of asthma or COPD
Disease burden in mild asthma
Factors associated with exacerbations in patients with COPD
Characteristics of patients with physician-assigned COPD without airflow limitation

19 PARTICIPATING COUNTRIES^a

~12,000 ENROLLED PATIENTS^a

84% OF PATIENTS HAVE SPIROMETRY DATA^b

You are now leaving: http://aznoveltyproject.com/

By following this link you will be leaving the NOVELTY study website.

Please note that AstraZeneca does not take responsibility for the content displayed on other websites.

Continue Return to NOVELTY study